Global Companion Diagnostic Tests Market is expected to grow at a CAGR of 7.2% during the forecast period, to reach USD 3.5 billion by 2030 from USD 2.4 billion in 2018. The market is driven by factors such as increasing prevalence of chronic diseases and rising demand for personalized medicine, which are driving the growth of companion diagnostic tests market globally.
Protein detection segment accounted for the largest share in global companion diagnostic tests market in 2018 and is expected to continue its dominance throughout the forecast period due to its high accuracy and specificity, which makes it suitable for use in clinical diagnosis as well as research purposes. Hybridization segment accounted for third-largest share in global companion diagnostic tests market with an estimated value of USD 1 billion by 2030 from USD 0.6 billion in 2018 due to its high accuracy and specificity, which makes it suitable for use both clinically and research purposes.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases will drive the Companion Diagnostic Tests market.
- Increasing government funding for research and development in the field of companion diagnostics will fuel the growth of this market.
- The increasing number of mergers and acquisitions in the pharmaceutical industry will lead to an increase in investments in companion diagnostics.
- The increasing number of collaborations between pharmaceutical companies and diagnostic companies will also fuel the growth.
Industry Growth Insights published a new data on “Companion Diagnostic Tests Market”. The research report is titled “Companion Diagnostic Tests Market research by Types (Protein Detection, DNA Detection, Hybridization, Biomarker, Others), By Applications (Pharmaceutical and Biotechnology Companies, Medical Device Companies, Research Institutes), By Players/Companies F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., BioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, Thermo Fisher Scientific, Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Companion Diagnostic Tests Market Research Report
By Type
Protein Detection, DNA Detection, Hybridization, Biomarker, Others
By Application
Pharmaceutical and Biotechnology Companies, Medical Device Companies, Research Institutes
By Companies
F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., BioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, Thermo Fisher Scientific, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Companion Diagnostic Tests Market Report Segments:
The global Companion Diagnostic Tests market is segmented on the basis of:
Types
Protein Detection, DNA Detection, Hybridization, Biomarker, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical and Biotechnology Companies, Medical Device Companies, Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffman LA Roche Ltd.
- QIAGEN, Illumina, Inc.
- Abbott
- Agilent Technologies, Inc.
- Genomic Health, Inc.
- BioMerieux SA, BioGenex
- AGENDIA NV
- Siemens Healthcare GmBH
- Thermo Fisher Scientific, Inc.
Highlights of The Companion Diagnostic Tests Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Protein Detection
- DNA Detection
- Hybridization
- Biomarker
- Others
- By Application:
- Pharmaceutical and Biotechnology Companies
- Medical Device Companies
- Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Companion Diagnostic Tests Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Companion diagnostic tests are a type of laboratory test that can be used in addition to other tests to help diagnose a medical condition. Companion diagnostic tests may be used together with other tests to help identify the cause of an illness or injury.
Some of the key players operating in the companion diagnostic tests market are F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., BioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, Thermo Fisher Scientific, Inc..
The companion diagnostic tests market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Companion Diagnostic Tests Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Companion Diagnostic Tests Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Companion Diagnostic Tests Market - Supply Chain
4.5. Global Companion Diagnostic Tests Market Forecast
4.5.1. Companion Diagnostic Tests Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Companion Diagnostic Tests Market Size (000 Units) and Y-o-Y Growth
4.5.3. Companion Diagnostic Tests Market Absolute $ Opportunity
5. Global Companion Diagnostic Tests Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Companion Diagnostic Tests Market Size and Volume Forecast by Type
5.3.1. Protein Detection
5.3.2. DNA Detection
5.3.3. Hybridization
5.3.4. Biomarker
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Companion Diagnostic Tests Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Companion Diagnostic Tests Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical and Biotechnology Companies
6.3.2. Medical Device Companies
6.3.3. Research Institutes
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Companion Diagnostic Tests Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Companion Diagnostic Tests Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Companion Diagnostic Tests Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Companion Diagnostic Tests Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Companion Diagnostic Tests Demand Share Forecast, 2019-2026
9. North America Companion Diagnostic Tests Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Companion Diagnostic Tests Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Companion Diagnostic Tests Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical and Biotechnology Companies
9.4.2. Medical Device Companies
9.4.3. Research Institutes
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Companion Diagnostic Tests Market Size and Volume Forecast by Type
9.7.1. Protein Detection
9.7.2. DNA Detection
9.7.3. Hybridization
9.7.4. Biomarker
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Companion Diagnostic Tests Demand Share Forecast, 2019-2026
10. Latin America Companion Diagnostic Tests Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Companion Diagnostic Tests Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Companion Diagnostic Tests Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical and Biotechnology Companies
10.4.2. Medical Device Companies
10.4.3. Research Institutes
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Companion Diagnostic Tests Market Size and Volume Forecast by Type
10.7.1. Protein Detection
10.7.2. DNA Detection
10.7.3. Hybridization
10.7.4. Biomarker
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Companion Diagnostic Tests Demand Share Forecast, 2019-2026
11. Europe Companion Diagnostic Tests Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Companion Diagnostic Tests Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Companion Diagnostic Tests Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical and Biotechnology Companies
11.4.2. Medical Device Companies
11.4.3. Research Institutes
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Companion Diagnostic Tests Market Size and Volume Forecast by Type
11.7.1. Protein Detection
11.7.2. DNA Detection
11.7.3. Hybridization
11.7.4. Biomarker
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Companion Diagnostic Tests Demand Share, 2019-2026
12. Asia Pacific Companion Diagnostic Tests Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Companion Diagnostic Tests Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Companion Diagnostic Tests Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical and Biotechnology Companies
12.4.2. Medical Device Companies
12.4.3. Research Institutes
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Companion Diagnostic Tests Market Size and Volume Forecast by Type
12.7.1. Protein Detection
12.7.2. DNA Detection
12.7.3. Hybridization
12.7.4. Biomarker
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Companion Diagnostic Tests Demand Share, 2019-2026
13. Middle East & Africa Companion Diagnostic Tests Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Companion Diagnostic Tests Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Companion Diagnostic Tests Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical and Biotechnology Companies
13.4.2. Medical Device Companies
13.4.3. Research Institutes
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Companion Diagnostic Tests Market Size and Volume Forecast by Type
13.7.1. Protein Detection
13.7.2. DNA Detection
13.7.3. Hybridization
13.7.4. Biomarker
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Companion Diagnostic Tests Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Companion Diagnostic Tests Market: Market Share Analysis
14.2. Companion Diagnostic Tests Distributors and Customers
14.3. Companion Diagnostic Tests Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. F. Hoffman LA Roche Ltd.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. QIAGEN, Illumina, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbott
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Agilent Technologies, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genomic Health, Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. BioMerieux SA, BioGenex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. AGENDIA NV
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Siemens Healthcare GmBH
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Thermo Fisher Scientific, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
